# Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants

> **NCT04410198** · PHASE3 · COMPLETED · sponsor: **Kyntra Bio** · enrollment: 203 (actual)

## Conditions studied

- Anemia Associated With End Stage Renal Disease (ESRD)

## Interventions

- **DRUG:** Roxadustat

## Key facts

- **NCT ID:** NCT04410198
- **Lead sponsor:** Kyntra Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-26
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-10-11
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2022-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04410198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04410198, "Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04410198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*